ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. Sutro Biopharma's annualizedNet Income for the quarter that ended in Mar. 2026 was €-133.16 Mil.
Sutro Biopharma's average Total Assets over the quarter that ended in Mar. 2026 was €178.89 Mil. Therefore, Sutro Biopharma's annualized ROA % for the quarter that ended in Mar. 2026 was -74.44%.
The historical rank and industry rank for Sutro Biopharma's ROA % or its related term are showing as below:
FRA:S090'
s ROA % Range Over the Past 10 Years
Min: -68.12 Med: -29.04 Max: 2.46
Current: -63.51
During the past 10 years, Sutro Biopharma's highest ROA % was 2.46%. The lowest was -68.12%. And the median was -29.04%.
FRA:S090's ROA % is ranked worse than 71.27% of 1420
companies
in the Biotechnology industry
Industry Median: -32.87
vs FRA:S090: -63.51
Sutro Biopharma (FRA:S090) ROA % Explanation
ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A banks ROA % is typically well under 2%.
Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:
Note:
The Net Income data used here is four times the quarterly (Mar. 2026) net income data. The Revenue data used here is four times the quarterly (Mar. 2026) revenue data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.
E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.
Sutro Biopharma ROA % Related Terms
Sutro Biopharma ROA % Historical Data
* Premium members only.
The historical data trend for Sutro Biopharma's ROA % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Sutro Biopharma's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sutro Biopharma ROA % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Sutro Biopharma's ROA % distribution charts can be found below:
* The bar in red indicates where Sutro Biopharma's ROA % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Mar. 2026) net income data.
ROA % is displayed in the 30-year financial page.
Sutro Biopharma (FRA:S090) has a ROA % of -74.44% as of Mar. 2026. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Sutro Biopharma and its competitors. According to the industry distribution chart, Sutro Biopharma ranks #1012 out of 1420 companies in the Biotechnology industry, placing it in the top 71.3%.
Is Sutro Biopharma's ROA % too high?
Sutro Biopharma's current ROA % is -74.44%. Based on the distribution chart, Sutro Biopharma ranks #1012 out of 1420 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Sutro Biopharma has a GF Score™ of 46/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Sutro Biopharma's ROA % compare to CCCC and OCGN?
According to the Biotechnology industry distribution chart, Sutro Biopharma ranks #1012 out of 1420 companies for ROA %. This places Sutro Biopharma in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROA % for a Biotechnology company?
A good ROA % depends on the Biotechnology industry context. However, ROA % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROA % mean?
A high ROA % can signal that a stock is expensive relative to its fundamentals. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Sutro Biopharma and its competitors. Sutro Biopharma's current ROA % is -74.44%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sutro Biopharma stock overvalued right now?
Based on GuruFocus' analysis, Sutro Biopharma (FRA:S090) is currently considered Significantly Overvalued. The stock's GF Value™ is €10.36, compared to a current price of €24.80 — trading 139.4% above its estimated fair value. The current ROA % is -74.44%. Sutro Biopharma's overall GF Score™ is 46/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROA % calculated?
ROA % is calculated from a company's financial statements. For Sutro Biopharma (FRA:S090), the current ROA % is -74.44% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sutro Biopharma (FRA:S090) Overvalued in 2026?
Based on GuruFocus' analysis, Sutro Biopharma stock appears to be overvalued.
The current stock price of €24.80 is trading 139.4% above its estimated GF Value™ of €10.36.
GuruFocus considers Sutro Biopharma to be Significantly Overvalued.
Key valuation signals for FRA:S090:
ROA %: -74.44%
GF Value™: €10.36 vs. price of €24.80 (139.4% above fair value)
No single metric tells the full story. See the FRA:S090 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. Company's wholly-owned product candidate is STRO-004, a single homogeneous ADC directed against tissue factor which are developing for the treatment of solid tumors. The company also pipeline contains STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.
46GF Score
Get the complete analysis for FRA:S090
ROA % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:S090 has been successfully added to your 
